Candel Therapeutics (CADL) Net Equity Issued and Repurchased (2024 - 2025)

Candel Therapeutics (CADL) posted Net Equity Issued and Repurchased of $4.7 million for Q2 2025, up 1111.98% sequentially from $384000.0 in Q1 2025, and up 34.7% YoY from $3.5 million in Q2 2024.

Candel Therapeutics (CADL) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends

Candel Therapeutics has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $4.7 million in Q2 2025.

  • Quarterly Net Equity Issued and Repurchased rose 34.7% year-over-year to $4.7 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (down 68.17% YoY) and the FY2025 annual result came in at $5.0 million, down 68.17% from the prior year.
  • Net Equity Issued and Repurchased grew to $4.7 million in Q2 2025 per CADL's latest filing, from $384000.0 in the prior quarter.
  • Over five years, Net Equity Issued and Repurchased peaked at $8.1 million in Q4 2024 and troughed at $186000.0 in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Candel Therapeutics 643.41 Mn 643.41 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 4.65 Mn
Jun 30, 2025 4.65 Mn
Mar 31, 2025 384,000.00
Mar 31, 2025 384,000.00
Dec 31, 2024 8.12 Mn
Dec 31, 2024 8.12 Mn
Sep 30, 2024 4.07 Mn
Sep 30, 2024 4.07 Mn
Jun 30, 2024 3.46 Mn
Jun 30, 2024 3.46 Mn
Mar 31, 2024 186,000.00
Mar 31, 2024 186,000.00